News

Filter

Infinity amends PI3K-delta, gamma accord with Millennium

28-12-2012

US drug discovery firm Infinity Pharmaceuticals (Nasdaq: INFI) says it has amended its development and…

BiotechnologyFinancialInfinity PharmaceuticalsIPI-145LicensingMillennium PharmaceuticalsPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Infinity regains global rights to PI3K, FAAH; equity investment by Purdue

20-07-2012

USA-based Infinity Pharmaceuticals (Nasdaq: INFI) says it has restructured its strategic alliance with…

FinancialInfinity PharmaceuticalsLicensingMundipharmaPharmaceuticalPurdue PharmaResearch

Mundipharma commits over $50 million in R&D funding for Infinity’s PI3K inhibitor

01-12-2011

Privately-held Mundipharma International as committed to providing over $50 million in funding in 2013…

FinancialInfinity PharmaceuticalsInflammatory diseasesLicensingMundi InternationalOncologyPharmaceuticalResearch

Back to top